All stocks / KPTIQ
KARYOPHARM THERAPEUTICS INC KPTIQ
Karyopharm Therapeutics (KPTIQ) on the Pink Limited market: listing details, recent company news and where to find its disclosures. Not matched to SEC records yet.
Pink LimitedMassachusetts, USA
SEC records not collected yet
This company files with the SEC, but its records have not been pulled yet. Signals and the plain-language financial report appear after the next daily run.
Search SEC EDGAR for this company Company disclosure on OTC Markets
Market listing
- Full name
- KARYOPHARM THERAPEUTICS INC
- Market tier
- OTC Pink Limited
- Trading status
- Active
- Last trade
- 09:10:54
- Website
- www.karyopharm.com
News headlines
Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO(TM) (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis
2026-11-17 07:30 · News Release
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
2026-11-04 09:01 · News Release
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
2026-11-02 07:10 · News Release
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 16:05 · News Release
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 16:05 · News Release
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO(TM) (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
2026-08-31 07:30 · News Release
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
2026-08-13 07:30 · News Release
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
2026-08-10 07:30 · News Release
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-03 16:05 · News Release
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
Headlines only, with links to the full item. Company press releases are written by the company. 2026-07-30 16:06 · News Release